Litigation Details for Abraxis BioScience, LLC v. HBT Labs, Inc. (D. Del. 2018)
✉ Email this page to a colleague
Abraxis BioScience, LLC v. HBT Labs, Inc. (D. Del. 2018)
| Docket | ⤷ Start Trial | Date Filed | 2018-12-19 |
| Court | District Court, D. Delaware | Date Terminated | 2020-02-11 |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | |
| Patents | 7,758,891; 7,820,788; 7,923,536; 8,034,375; 8,138,229; 8,268,348; 8,314,156; 8,853,260; 9,101,543; 9,101,545; 9,393,318; 9,511,046; 9,597,409 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Abraxis BioScience, LLC v. HBT Labs, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷ Start Trial and ⤷ Start Trial .
Details for Abraxis BioScience, LLC v. HBT Labs, Inc. (D. Del. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-12-19 | External link to document | |||
| 2018-12-19 | 17 | 1402 Patents-in-Suit in twelve separate counts, as follows: United States Patent Nos. 7,758,891 (891 …Tithe of Patent : _?) “Glanmed Use 0°: I fF 28-36: Ex A 7,758,891 | “Combinations and modes of | “A method…891 patent,” Count I; 7,820,788 (788 patent,” Count ID), 7,923,536 ¢°536 patent,” Count UD), 8,034,375 (… (°375 patent,” Count IV), 8,138,229 (229 patent,” Count V), 8,268,348 (348 patent,” Count V1), 8,314,…8,314,156 (° 156 patent,” Count VII), 8,853,260 (°°260 patent,” Count VII), 9,101,543 (543 patent,” Count IX | External link to document | |
| 2018-12-19 | 36 | Order - -Memorandum and Order | The patents-in-suit include United States Patent Nos. 7,758,891 ("the '891 patent"),…in a patent or the use of which is claimed in a patent before the expiration of such patent. …infringement of twelve patents under 35 U.S.C. § 271(e). (D.I. 1). The patents-in-suit 1 relate to various… ("the '788 patent"), 7,923,536 (''the '536 patent"), 8,034,375 ("…"the '375 patent"), 8,138,229 ("the '229 patent"), 8,268,348 ('' | External link to document |
| 2018-12-19 | 4 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,758,891 B2 ;7,820,788 B2 ;7,923,536… 11 February 2020 1:18-cv-02019 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | |
| 2018-12-19 | 6 | States Patent Nos. 7,758,891 (“’891 patent”), 7,820,788 (“’788 patent”), 7,923,536 (“’536 patent”), 8,…(“’375 patent”), 8,138,229 (“’229 patent”), 8,268,348 (“’348 patent”), 8,314,156 (“’156 patent”), 8,853,260…(“’260 patent”), 9,101,543 (“’543 patent”), 9,393,318 (“’318 patent”), 9,511,046 (“’046 patent”), and… 1. This is an action for patent infringement under the patent laws of the United States, 35 U.S.C…and 9,597,409 (“’409 patent”), all owned by Abraxis (collectively, the “patents-in-suit”). | External link to document | |
| 2018-12-19 | 65 | Notice of Service | Invalidity Contentions Relating to U.S. Patent Nos. 7,820,788, 7,923,536, 8,138,229 filed by HBT Labs,… 11 February 2020 1:18-cv-02019 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2018-12-19 | 76 | Judgment - Consent | Judgment, the term "Patents-in-Suit" shall mean U.S. Patent Nos. 7,758,891; 7,820,788 ; 7,923… 4. Until expiration of the Patents-in-Suit, HBT, including any of its successors…successors and assigns, is enjoined from infringing the Patents-in-Suit, on its own part or through II Case…parties in connection with any infringement of the Patents-in-Suit by any such third parties, unless…to 21 C.F.R. § 314.52(c)(l) with respect to the Patents-in-Suit. 9. Nothing herein | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
